Physician profile
Eric Waki
NPI 1306866462
$2,902.85
in general payments reported to CMS, 2019-2025
15 companies · $539 in 2025
The $539 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $360 · 2021: $411 · 2022: $563 · 2023: $533 · 2024: $159 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $691.77 | 2019-2025 | |
| Stryker Corporation | $684.67 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $661.77 | 2021-2025 | Dupixent |
| Optinose US, INC. | $211.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $150.22 | 2021-2023 | Nucala |
| Inspire Medical Systems, INC. | $100.58 | 2024-2025 | Inspire |
| Acclarent, INC | $92.63 | 2019-2023 | Trudi Nav Cable, Acclarent Aera |
| Medtronic, INC. | $62.46 | 2023-2025 | Propel, Sinuva |
| Intersect Ent, INC. | $50.06 | 2021-2022 | |
| Aerin Medical INC. | $46.67 | 2025 | |
| Alk-Abello, INC | $42.96 | 2020-2022 | |
| Smith+Nephew, INC. | $34.64 | 2025 | Tula |
| Novartis Pharmaceuticals Corporation | $30.74 | 2019-2021 | |
| Boston Scientific Corporation | $25.62 | 2025 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $17.04 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Waki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.